<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01073839</url>
  </required_header>
  <id_info>
    <org_study_id>ONK USZ 001-2008</org_study_id>
    <nct_id>NCT01073839</nct_id>
  </id_info>
  <brief_title>Adjuvant Cisplatin Plus Gemcitabine in Operable Cholangiocellular Carcinoma.</brief_title>
  <official_title>Adjuvant Treatment of Resectable Cholangiocellular Carcinoma (CCC) With Cisplatin Plus Gemcitabine. A Prospective Single Center Phase Ib-II Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Zurich</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Zurich</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      OBJECTIVES&#xD;
&#xD;
      Primary objective:&#xD;
&#xD;
      The primary objective of the trial is to determine the safety of adjuvant treatment with&#xD;
      cisplatin plus gemcitabine for a period of 6 months after curative resection of&#xD;
      cholangiocellular carcinoma&#xD;
&#xD;
      Secondary objectives:&#xD;
&#xD;
      Secondary objectives of the trial are to assess the feasibility and efficacy of the adjuvant&#xD;
      therapy and to determine duration of response and patterns of failure compared to historical&#xD;
      controls without postoperative treatment&#xD;
&#xD;
      Exploratory objectives:&#xD;
&#xD;
      To obtain blood samples and tumor tissue after resection for establishment and&#xD;
      characterization of new cholangiocarcinoma cell lines and tumor antigens. Other aims are&#xD;
      identification of tumor specific antibodies from blood samples, and characterization of tumor&#xD;
      antigens with consecutive development of new specific immunological therapies, e.g.&#xD;
      cancer-testis antigens (CTA) for tumor vaccination.&#xD;
&#xD;
        -  Trial with medicinal product&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2008</start_date>
  <completion_date type="Actual">August 2015</completion_date>
  <primary_completion_date type="Actual">August 2015</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Occurence of Grade 3 or 4 toxicities according to NCI-common terminology criteria for adverse events v3.0</measure>
    <time_frame>One year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease-free survival</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">33</enrollment>
  <condition>Cholangiocellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>Cisplatin plus Gemcitabine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients after resection of cholangiocellular carcinoma will be allocated to treatment with cisplatin plus gemcitabine.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin and Gemcitabine</intervention_name>
    <description>Cisplatin 25 mg/m2 days 1 and 8; next cycle starting day 22. Gemcitabine 1000 mg/m2 days 1 and 8; next cycle starting day 22. Total of 8 cycles.</description>
    <arm_group_label>Cisplatin plus Gemcitabine</arm_group_label>
    <other_name>Gemzar</other_name>
    <other_name>Platinol</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria&#xD;
&#xD;
          1. Histologically or cytologically confirmed adenocarcinoma of biliary tract&#xD;
             (intrahepatic and hilar tumors). Carcinomas involving the gall bladder are allowed.&#xD;
&#xD;
          2. Macroscopically complete resection within 8 weeks before start of chemotherapy.&#xD;
&#xD;
          3. Written informed consent.&#xD;
&#xD;
          4. Health status: WHO performance status (PS) 0-1&#xD;
&#xD;
          5. Age &gt;18 years&#xD;
&#xD;
          6. Adequate renal function (creatinine clearance ≥ 60 ml/min, calculated according to the&#xD;
             formula of Cockcroft-Gault)&#xD;
&#xD;
          7. Adequate hepatic function (bilirubin ≤ 3 x LUN, AP ≤ 5 x LUN, ASAT ≤ 5 x LUN)&#xD;
&#xD;
          8. Adequate hematologic function: neutrophils ≥ 1.5 x 109/l, platelets ≥ 100 x 109/l, Hb&#xD;
             ≥ 9,5 mg/dl&#xD;
&#xD;
          9. Patient compliance and geographic proximity allowing proper staging, treatment and&#xD;
             follow-up.&#xD;
&#xD;
         10. Women who are not breastfeeding and are using effective contraception if sexually&#xD;
             active, who are not pregnant and agree not to become pregnant during participation in&#xD;
             the trial or during the 12 months thereafter. A negative pregnancy test before&#xD;
             inclusion into the trial is required for women &lt; 50 years. Men who agree not to father&#xD;
             a child during participation in the trial or during the 12 months thereafter.&#xD;
&#xD;
        Exclusion criteria&#xD;
&#xD;
          1. Pregnancy or breastfeeding women&#xD;
&#xD;
          2. Previous malignancy within 5 years or concomitant malignancy, except: non-melanomatous&#xD;
             skin cancer or adequately treated in situ cervical cancer&#xD;
&#xD;
          3. neutrophils &lt; 1.5 x 109/l, platelets &lt; 100 x 109/l, Hb &lt; 9,5 mg/dl&#xD;
&#xD;
          4. bilirubin &gt; 3 x LUN, ALAT &gt; 5 x LUN, ASAT &gt; 5 x LUN&#xD;
&#xD;
          5. Creatinine clearance &lt; 60 ml/min, calculated according to the formula of&#xD;
             Cockcroft-Gault&#xD;
&#xD;
          6. Prior chemotherapy with gemcitabine&#xD;
&#xD;
          7. Severe or uncontrolled cardiovascular disease (congestive heart failure NYHA III or&#xD;
             IV, unstable angina pectoris, history of myocardial infarction in the last 3 months,&#xD;
             significant arrhythmias)&#xD;
&#xD;
          8. Psychiatric disorder precluding understanding of information of trial related topics&#xD;
             and giving informed consent&#xD;
&#xD;
          9. Active uncontrolled infection&#xD;
&#xD;
         10. Preexisting peripheral neuropathy (&gt; grade 1)&#xD;
&#xD;
         11. Serious underlying medical condition (judged by the investigator) which could impair&#xD;
             the ability of the patient to participate in the trial (e.g. uncontrolled diabetes&#xD;
             mellitus, active autoimmune disease)&#xD;
&#xD;
         12. Concurrent treatment with other experimental drugs or other anti-cancer therapy;&#xD;
             treatment in a clinical trial within 30 days prior to trial entry&#xD;
&#xD;
         13. Known hypersensitivity to the study drugs&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>01 Studienregister MasterAdmins</last_name>
    <role>Study Director</role>
    <affiliation>UniversitaetsSpital Zuerich</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Zurich</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>September 2015</verification_date>
  <study_first_submitted>June 25, 2009</study_first_submitted>
  <study_first_submitted_qc>February 22, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 23, 2010</study_first_posted>
  <last_update_submitted>September 17, 2015</last_update_submitted>
  <last_update_submitted_qc>September 17, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 18, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Zurich</investigator_affiliation>
    <investigator_full_name>Bernhard Pestalozzi</investigator_full_name>
    <investigator_title>Prof. Dr. med.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Cholangiocarcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

